Accelerate Diagnostics Gross Profit Over Time

AXDX Stock  USD 1.70  0.13  8.28%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Accelerate Diagnostics Performance and Accelerate Diagnostics Correlation.
For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.
  
Gross Profit is likely to drop to about 1.6 M in 2024. Gross Profit Margin is likely to drop to 0.20 in 2024.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accelerate Diagnostics. If investors know Accelerate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accelerate Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.59)
Revenue Per Share
0.665
Quarterly Revenue Growth
0.022
Return On Assets
(0.76)
The market value of Accelerate Diagnostics is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnostics' market value can be influenced by many factors that don't directly affect Accelerate Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accelerate Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Accelerate Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Gross Profit Analysis

Compare Accelerate Diagnostics and related stocks such as CVRx Inc, Neuropace, and Anika Therapeutics Gross Profit Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
CVRX4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M9.4 M17.5 M33 M34.7 M
NPCE26.5 M26.5 M26.5 M26.5 M26.5 M26.5 M26.5 M26.5 M26.5 M26.5 M30.3 M33.4 M32.5 M48.1 M37.6 M
ANIK300 K38 M42.4 M52.3 M84.7 M71.9 M79.4 M86.1 M74.3 M85.9 M69 M82.9 M93.6 M103.1 M108.2 M
AXGN700 K2.4 M5.7 M8.5 M13.4 M22.5 M34.6 M51.1 M71 M89.4 M90.7 M104.4 M114.4 M127.9 M134.3 M
AORT8.2 M75.8 M85 M90.4 M91.3 M90.7 M118.9 M128.6 M173 M183 M167.8 M197.5 M202.5 M229.2 M240.6 M
SGHT5.2 M5.2 M5.2 M5.2 M5.2 M5.2 M5.2 M5.2 M5.2 M16.8 M18.4 M40.3 M59 M69.2 M38.3 M
OFIX20.9 M439.8 M375.8 M298.2 M303.4 M310 M321.9 M340.8 M356.4 M359.3 M304.7 M349.6 M337.2 M486.3 M259.2 M
AVNS590.8 M590.8 M602.5 M612.2 M548.6 M531.6 M557.9 M336.9 M390.9 M402.2 M373.3 M364.3 M450 M379.7 M377.9 M
CNMDM374.9 M405.8 M406.5 M398.5 M381.7 M408.3 M431 M469.1 M524.7 M460.3 M568 M571.2 M676.2 M710.1 M
KIDS16.6 M16.6 M16.6 M16.6 M16.6 M21.6 M26.4 M34.5 M42.7 M54.6 M55 M73.4 M90.7 M111.3 M57.9 M
SRDX9.3 M44.5 M33.2 M33.9 M37.1 M42 M29.9 M26.4 M33.6 M29.4 M41.2 M29 M61 M93.1 M49.1 M
ITGR38.2 M180.4 M201.6 M219.3 M231.4 M235.1 M378.3 M393.6 M362.7 M355 M285.7 M337 M359 M418.3 M226.6 M
LIVN200 K198.8 M232.4 M254.7 M264.2 M266.5 M704.4 M651.6 M734.5 M744.8 M618.2 M706 M707.2 M771.2 M809.8 M
ELMD6.6 M14.1 M10.4 M10.6 M13.6 M17.9 M20.6 M22.9 M23.8 M25.2 M27.3 M31.4 M36.5 M41.7 M21.8 M
LUNG115 K115 K115 K115 K283.2 K3.9 K(1.4 K)0.012.3 M22.4 M21.2 M35.6 M39.9 M50.8 M53.3 M
IRMD5.6 M5.6 M5.6 M8.5 M12.2 M25.8 M26.3 M17.5 M23.2 M29.7 M23.6 M32 M41.3 M50.2 M27.1 M

Accelerate Diagnostics and related stocks such as CVRx Inc, Neuropace, and Anika Therapeutics Gross Profit description

Gross profit is a required income statement account that reflects total revenue of Accelerate Diagnostics minus its cost of goods sold. It is profit before Accelerate Diagnostics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

My Equities

My Current Equities and Potential Positions

Accelerate Diagnostics
AXDX
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationArizona; U.S.A
ExchangeNASDAQ Exchange
USD 1.7

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.